ProstaLund AB today announces that the Swedish Patent and Registration Office (PRV) has announced that it intends to approve the company's patent application 2150095-4, which relates to a kit consisting of the company's product Schelin Catheter® together with anesthetic, BOTOX®* or penicillin. The patent number is 544,983 and the patent is valid until 2041. This particular patent family also includes previously granted utility patent in China (in February 2022) as well as ongoing applications in the US and an international PCT application that will be completed in at least Europe.

Schelin Catheter® is a device designed to be used to administer local anesthesia in the prostate. The product is not specially adapted for ProstaLund's own method, CoreTherm®, but is compatible with a variety of methods where local anesthesia of the prostate is needed.

"The granted product patent will have great value for ProstaLund, given that the product will be used outside Sweden's borders in various areas of use. We have always felt safe in our patent situation, but it means a lot to have it confirmed by PRV. Now that we have had this patent granted, we end up in an even more interesting position in discussions with future potential partners and other stakeholders.", says CEO Johan Wennerholm in a comment.

*BOTOX® and its design are registered trademarks of Allergan, Inc., an AbbVie company.

For further information, please contact:

Johan Wennerholm,  CEO
Tel. +46 (0) 730 429997
Email: johan.wennerholm@prostalund.com

About ProstaLund

ProstaLund AB is a Swedish medical technology company and a leading developer and manufacturer of innovative urological devices and treatments. The company’s lead product, CoreTherm, is a patented Thermotherapy treatment method for Benign Prostatic Hyperplasia (BPH) which can be tailored to suit the needs of each individual patient. CoreTherm is used today in hospitals and clinics in Sweden and worldwide. ProstaLund is listed on the Nasdaq First North Growth Market.

Certified Adviser:
Västra Hamnen Corporate Finance AB
Phone: +46 40 200 250
E-mail: ca@vhcorp.se

Attachments

ProstaLund will receive a patent in Sweden

© Modular Finance, source Nordic Press Releases